Nuala Brennan
Chief Tech/Sci/R&D Officer at MOONLAKE IMMUNOTHERAPEUTICS
Profile
Ms. Nuala Brennan is a Chief Clinical Development Officer at MoonLake Immunotherapeutics and a Chief Clinical Development Officer at Moonlake Immunotherapeutics Ltd.
Ms. Brennan was previously employed as a Vice President-Clinical Operations by Kymab Ltd.
She received her undergraduate degree from the University of Leicester.
Nuala Brennan active positions
| Companies | Position | Start |
|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS | Chief Tech/Sci/R&D Officer | 31/08/2021 |
| Moonlake Immunotherapeutics Ltd. | Chief Tech/Sci/R&D Officer | 31/08/2021 |
Former positions of Nuala Brennan
| Companies | Position | End |
|---|---|---|
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Chief Tech/Sci/R&D Officer | 31/07/2021 |
Training of Nuala Brennan
| University of Leicester | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS | Health Technology |
| Private companies | 2 |
|---|---|
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| Moonlake Immunotherapeutics Ltd. |
- Stock Market
- Insiders
- Nuala Brennan